- Home
- PRAX vs TERN Comparison
PRAX vs TERN Comparison
Compare PRAX & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRAX | TERN |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.8B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PRAX | TERN |
|---|---|---|
| Price | $267.06 | $44.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 10 |
| Target Price | ★ $304.43 | $48.60 |
| AVG Volume (30 Days) | 1.1M | ★ 5.2M |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,463,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 364.98 | N/A |
| 52 Week Low | $26.70 | $1.87 |
| 52 Week High | $278.44 | $48.26 |
Technical Indicators
Market Signals| Indicator | PRAX | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 71.53 | 79.72 |
| Support Level | $251.00 | $25.67 |
| Resistance Level | $278.44 | $48.26 |
| Average True Range (ATR) | 17.08 | 3.43 |
| MACD | 6.49 | 1.45 |
| Stochastic Oscillator | 90.84 | 83.71 |
Price Performance
Historical ComparisonAbout PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.